

Applicants: David M. Stern et al.
U.S. Serial No.: 09/374,213
Filed: August 13, 1999
Page 2

Amendments to the Specification

Please delete the following paragraph beginning on page 1, line 5:

This application claims priority of U.S. Serial No. 08/592,070, filed January 26, 1996 and of U.S. Serial No. 08/948,131, filed October 9, 1997 under U.S.C. §120, the contents of which are hereby incorporated by reference into the present application.

09374243 054309
00000000 00000000

μl/animal) treated with AEF/SN + vehicle or AEF/SN + sRAGE (100 μg; day 5) was immunoprecipitated with anti-apoSAA IgG (5 μg/ml), anti-RAGE IgG (5 μg) or IgG from preimmune serum (5 μg/ml) followed by SDS-PAGE/immunoblotting with

5 anti-apoSAA IgG (1 μg/ml; reduced 5-20% gel; 7I1) or anti-RAGE IgG (1 μg/ml; reduced 10% gel; 7I2). Panel 1: lane 1, immunoprecipitation of plasma from AEF/SN + sRAGE mice with anti-RAGE IgG followed by immunoblotting with anti-apoSAA IgG; lane 2, immunoprecipitation of plasma from

10 AEF/SN+sRAGE mice with preimmune IgG followed by immunoblotting with anti-apoSAA IgG; and, lane 3, immunoblotting of AEF/SN plasma with anti-apoSAA IgG. Panel 2: lane 1, immunoprecipitation of plasma from AEF/SN+sRAGE mice with anti-apoSAA IgG followed by immunoblotting with

15 anti-RAGE IgG; lane 2, immunoprecipitation of plasma from AEF/SN+sRAGE mice with preimmune IgG followed by immunoblotting with anti-RAGE IgG; and, lane 3, immunoblotting of purified sRAGE (1 μg). Immunoprecipitation of plasma from AEF/SN mice not treated

20 with sRAGE showed no detectable sRAGE and no evidence of SAA-sRAGE complex. * indicates $p < 0.01$. Studies were repeated a minimum of three times, and there were five animals in experimental groups. Magnification: D x80; E x280; H x80.

25

Figure 8. Dissociation constants for the interaction of RAGE with several peptides in solution evaluated by fluorescence.

30